Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 92Recurrence 11Neoplasms, Plasma Cell 9Lymphoma 8Lymphoma, Mantle-Cell 6Waldenstrom Macroglobulinemia 5Smoldering Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Hodgkin Disease 2Hematologic Neoplasms 2Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1

Interventions

gallium Ga 68 dotatate 5Everolimus 5lanreotide 3cabozantinib 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2Temozolomide 2Sunitinib 2Octreotide 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1nintedanib 1ibrutinib 1ganitumab 1fluorodopa F 18 1carfilzomib 1aflibercept 1Sorafenib 1Somatostatin 1Serotonin 1Ramucirumab 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoid Tumor × carfilzomib × Clear all
NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
62 enrolled 10 charts
Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡